340 related articles for article (PubMed ID: 36692409)
1. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract][Full Text] [Related]
3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
4. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Xu X; Liu R; He A; Wang F
Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
[TBL] [Abstract][Full Text] [Related]
5. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.
Inguva A; Pollyea DA
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):805-811. PubMed ID: 34389272
[TBL] [Abstract][Full Text] [Related]
11. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
13. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
[No Abstract] [Full Text] [Related]
16. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
[TBL] [Abstract][Full Text] [Related]
18. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
De Bellis E; Imbergamo S; Candoni A; Liço A; Tanasi I; Mauro E; Mosna F; Leoncin M; Stulle M; Griguolo D; Pravato S; Trentin L; Lazzarotto D; Di Bona E; Bassan R; Lucchini E; Poiani M; Palmieri C; Zaja F
Leuk Res; 2022 Mar; 114():106803. PubMed ID: 35150967
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
Ball BJ; Koller PB; Pullarkat V
Curr Opin Oncol; 2022 Sep; 34(5):531-539. PubMed ID: 35855507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
